Biotechnology: German Industry Beefs Up

June 1, 2001
Kevin Gopal
Kevin Gopal

Kevin Gopal is Pharmaceutical Executive's international correspondent, covering pharma and regulatory issues around the word. He is also a political columnist for North West Business Insider, one of the UK's leading regional business magazines. He started his career as a journalist at SiYu, the UK's Chinese community magazine, before joining the PE staff.

Pharmaceutical Executive

Pharmaceutical Executive, Pharmaceutical Executive-06-01-2001, Volume 0, Issue 0

Schering’s commitment to biotechnology in the early 1990s was a landmark decision for the company, says Dr. Guiseppe Vita, who is stepping down as chairman of the Berlin-based company. The result of that commitment was Betaferon (interferon beta-Ib), one of the first biotech products on the market in Germany. It is now Schering’s biggest product and one of the top ten best selling biotech therapies in the world.

Related Content:

News